MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University...
-
Upload
austen-warren -
Category
Documents
-
view
213 -
download
0
Transcript of MANAGEMENT OF INTRACEREBRAL HEMORRHAGE Navaz Karanjia, MD Director of Neurocritical Care University...
MANAGEMENT OF INTRACEREBRAL HEMORRHAGENavaz Karanjia, MD
Director of Neurocritical Care
University of California – San Diego
Intracerebral Hemorrhage
Intracerebral Hemorrhage
Intracerebral Hemorrhage
Neurocritical Care Management of Intracerebral Hemorrhage Epidemiology
10-15% of all strokes, 50-70,000 cases/yr in US Presentation
Headache, neurologic deficit Outcomes
40% 30-day mortality Reduced by 17% by an NCCU/neurointensivist
20% independent at 6 monthsImproves by 21% by an NCCU/neurointensivist
Mirski M, Chang CW, and Cowan R. J Nsurg Anesth 2001; 13(2): 83-92.
Lancet Neurol. 2010 Feb;9(2):167-76. doi: 10.1016/S1474-4422(09)70340-0
Intracerebral Hemorrhage
Causes of ICH
Intracerebral Hemorrhage
Common locations for hypertensive ICH
Thalamus Cerebellum Pons Basal Ganglia
Intracerebral Hemorrhage
Clinical course and complications
Tissue dissection, displacement, increased ICP (immediate)
Hematoma expansion (immediate ->36h)HydrocephalusNeurohemoinflammation/Cerebral edema (day 2-5)SeizuresCentral fever
Intracerebral Hemorrhage
Hematoma expansion72% have some hematoma expansion over 24h
38% have clinically significant expansion within 24h
Within 1 hr in 26% of casesWorsens outcome
Neurocritical Care Management of Intracerebral Hemorrhage Preventing hematoma expansion (INTERACT,
ATACH) IMMEDIATE BP control reduces expansion 30%
Target SBP 140-150 with nicardipine drip or labetalol/hydralazine IVP WITHIN 10 MINUTES
IMMEDIATE coagulopathy reversal FFP, PCC (KCentra) within 30 minRecheck coags 15 min post PCCPlatelets if <100,000 or TEG abnlNOT factor VII (FAST trial)Time to reversal is being tracked
PCC (Profilnine) Pathway
History of thrombotic event in past 6 wks? (DVT, PE, trauma, ischemic stroke, ACS, mesenteric ischemia, etc)Major surgery within 6 weeks? Heparin induced thrombocytopenia (HIT)?
UCSD Reversal Protocol for Spontaneous Intracerebral Hemorrhage with INR > 1.4
• INR 2-4: infuse 25 units/kg body weight* Profilnine over 5 min, not to exceed 2ml/min
• INR >4: infuse 40 units/kg body weight* Profilnine over 10 minutes, not to exceed 2ml/min
• Repeat INR 15 minutes after infusion complete. If INR not at target, repeat q15 min x2 until INR at target. Once INR ≤1.4, repeat INR every 6 hrs for 24 hrs. If INR > 145, give another 10mg vitamin K IV/PO and consider 2 more units FFP.
• If INR does not reach target in 45 minutes, consider Factor 7, 20-40 mcg/kg (1-3mg) IV x 1
At 24 hrs, repeat dose of Vitamin K 10 mg IV/PO * in obese patients, base dose on a maximum weight of ideal body weight + 20% ***
Check the following labs at 1 hr and q6 hrs after completion of PCC infusion: PT/INR, EKG and Cardiac enzymes, Fibrinogen
INR > 2.0
• STAT Labs: PT/INR, PTT, fibrinogen, platelets, CBC, Type and Screen, troponin• If crash craniotomy considered, type and cross 2U PRBC
• Give vitamin K 10mg IV stat; if IV not available, give 10mg PO• Transfuse 2U FFP stat over 30 min. If type&screen will take >30 min and INR>2, transfuse 2U
uncrossmatched FFP. If pt cannot tolerate FFP due to volume overload, use PCC+Factor 7 20-40mcg/kg (1-3 mg)
FFP Pathway
• Immediately give 2 more units FFP • Repeat coags upon completion of infusion• If INR still >1.4, 2 more units FFP • If still > 1.4, consider PCC and consult hematology• Once INR ≤1.4, repeat INR q4-6 hrs for 24-48 hrs
Can patient tolerate more FFP (volume status)?YES
NO YES
INR 1.4 – 2.0
NO
Stat labs at 15 min and q6 hours after completion of PCC infusion: PT/INR, TT, EKG, cardiac enzymes, fibrinogen, anti-Xa level. If TT or PT/INR is still prolonged AND patient still bleeding/extreme risk of hematoma expansion, consider repeating Profilnine dose or giving Factor 7, 20-40mcg/kg (1-3mg) IV x1
UCSD Reversal Protocol for Spontaneous Intracerebral Hemorrhage on Dabigatran, Rivaraoxaban, or Apixaban
• STAT labs: PT/INR, fibrinogen, platelets, CBC, PTT, TT, anti-Xa level , Type & Screen• If crash craniotomy considered, type and cross 2U PRBC
IF ON DABIGATRAN (direct thrombin inhibitor )
and TT prolongedIF ON RIVAROXABAN or APIXABAN (factor Xa inhibitor)
and PT/INR is prolonged or anti-Xa level elevated
IF ingestion within 2 hrs, give one dose activated charcoal orally
• infuse 25 units/kg (+/- 10%) body weight* PCC (Profilnine) over 5 minutes, not to exceed 2ml/min• Transfuse 2 units FFP STAT. If type and screen will take >30 min, transfuse 2 units uncrossmatched FFP.
Emergent dialysis may be considered in certain circumstances (renal failure, overdose); ~ 65% removed by hemodialysis
Dabigatran t ½ = 14 hrs (up to 34 hrs in severe renal impairment)
Rivaroxaban and Apixaban are NOT dialyzable
Rivaroxaban t 1/2 = 9 hrs (longer in renal impairment)Apixaban t ½ = 12 hrs (longer in renal impairment)
* in obese patients, use maximum weight of ideal body weight + 20%
Neurocritical Care Management of Intracerebral Hemorrhage Acute obstructive hydrocephalus
occurs in 50-70% of IVH patients treat with emergent EVD Intraventricular tPA for IVH clears IVH faster (11.4-
>2.6 days), likely reduces hydrocephalus/need for VP shunt, ? mortality/outcomes (CLEAR-IVH)
Huttner HB, Tognoni E et al. Eur J Neurol. 2008;15(4):342.
Intracerebral Hemorrhage
Neurohemoinflammation/cerebral edemaPeaks days 2-5Exacerbated by fever and seizureMedical cerebral edema treatment ((hypertonic saline, normothermia, seizure control, ventilation control)
Surgical/endoscopic clot removal
Neurocritical Care Management of Intracerebral HemorrhageSurgical clot removal (MISTIE II, STICH II trials)Endoscopic for deep clots
Improves good outcome 20% 34%
Open for all superficial clotsReduces mortality (STICH II)
Neurocritical Care Management of Intracerebral Hemorrhage
MISTIE II
Hanley, D et al. Mistie II Trial Results: 365 day outcome and cost-benefit. ISC 2013 Late Breaking Newshttp://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/downloadable/ucm_449055.pdf
Seizure control33% of altered ICH patients have seizures, most are nonconvulsiveSeizures worsen ICP, midline shiftAll altered ICH pts should receive
continuous EEG monitoring (Class I, LOE B )
Claassen et al. Anesthesia Analg. Vol. 109, No. 2, August 2009
2012 Neurocritical Care Society Guidelines:
Indications for Continuous EEG
Monitoring
Neurocritical Care Management of Intracerebral Hemorrhage
Neurocritical Care Management of Intracerebral Hemorrhage
Vespa et al Neurology 2003
Seizures after ICH leads to worsening midline shift
Neurocritical Care Management of Intracerebral Hemorrhage
Vespa et al Neurology 2003
Seizures after ICH leads to worsening midline shift
Neurocritical Care Management of Intracerebral Hemorrhage
Vespa et al Neurology 2003
Seizures after ICH leads to worsening midline shift
Intracerebral Hemorrhage
Antiepileptics are indicated ONLY if the patient demonstrates evidence of seizure clinically or on EEG (prophylactic AED’s worsen outcome, OR mRS>3 = 9.8).
Class I, LOE B
AED PROPHYLAXIS?
Naidech et al, Stroke 2009
Intracerebral Hemorrhage
Central feverOccurs in 70% of patientsIncreases cerebral metabolic rate, ICP, and midline shiftNormothermia should be maintained and fever treated aggressively, using antipyretics and intravascular/surface cooling devices if needed (Class I, LOE B recommendation)
Neurocritical Care Management of Intracerebral Hemorrhage
Normothermia, glycemic control, dysphagia screening
Lancet 2011: For all hemorrhagic and ischemic stroke patients, implementation of an RN protocol to treat any temp≥37.5, glycemic control, dysphagia screening decreases death/dependence 58% -> 42%, NNT 6.4
Intracerebral Hemorrhage
Neurocritical Care Management of Intracerebral Hemorrhage